Navigation Links
New target for cancer therapy may improve treatment for solid tumors
Date:3/3/2008

Targeting and killing the non-malignant cells that surround and support a cancer can stop tumor growth in mice, reports a research team based at the University of Chicago Medical Center in the March 1, 2008, issue of the journal Cancer Research. The discovery offers a new approach to treating cancers that are resistant to standard therapy.

Many solid tumors develop elaborate mechanisms to prevent recognition and elimination by the immune system. Due to their genetic instability they often discard the tumor antigen-presenting cell-surface structures that alert the immune system that these cells are harmful. Without these flags, the white blood cells fail to recognize and kill infected or cancerous cells. These tumors then often grow rapidly and resist treatment with chemotherapy or efforts to boost the immune system's response to the tumor.

But the stroma, the layers of cells that surround a tumor, can accumulate tumor antigens and present them on their surface. These genetically stable surrounding cells retain the molecules that present tumor antigens, which makes them a good target for immunotherapy, and they often play an enabling role in tumor growth.

We already knew that targeting the stroma is essential for eradicating established large tumors, because the stroma is like the 'root of the tumor," said study author Hans Schreiber, MD, PhD, professor of pathology at the University of Chicago. However, effects of current treatments that target stroma are usually transient and not cancer-specific."

"Since cancer is a genetic disease," he said, "we wondered whether mutant proteins are released into the surroundings and picked up by the stroma. If so, we can target the root of the cancer in a cancer-specific way to arrest or eradicate a tumor."

They injected T cells, the immune system's warriors, into mice with large established cancers. These T cells, specifically engineered to recognize the tumor antigen, had no direct impact on the cancerous cells but managed to kill stromal cells. This reduced tumor size and stopped the growth of tumors for more than 80 days.

Although targeting the stroma didn't eliminate all cancer cells, it did stop or slow the growth of well-established cancers after a single injection of T cells.

Such growth arrest in patients would be an admirable achievement for many cancers, the authors write, "and could also be used as an adjuvant to other therapies."

Tumor eradication is obviously preferable to tumor arrest, the authors note. "We can't target cancer cells when they have lost their antigen-presenting molecules, said co-author Bin Zhang, PhD, a former postdoctoral fellow in Schreiber's laboratory and now assistant professor at the University of Texas Health Sciences Center, San Antonio. So stroma becomes an ideal alternative target for T cells."

One concern was that other, healthy cells in tissues like the spleen could also pick up the antigens and become a target for T cells, said Zhang. We did not see this," he added. "Only tumor-derived stromal cells appear to pick up and present tumor antigen.

The next step is to test this approach for melanoma, breast and colon cancer, Zhang said. We know that stromal cells often present tumor-antigen in these tumors, but have not yet performed T cell therapy on these mice.

They are also studying this approach for human cancers. Early results suggest that "this approach might be useful for the human situation as well, Zhang said.


'/>"/>

Contact: John Easton
john.easton@uchospitals.edu
773-702-6241
University of Chicago Medical Center
Source:Eurekalert

Related medicine news :

1. New study of targeted therapies for breast cancer -- model for global clinical trials
2. Weill Cornell team identifies potential new drug targets against hormone-dependent breast cancer
3. Researchers find possible target to treat deadly bloodstream infections
4. Most Internet Sex Offenders Target Teens, Not Kids
5. Novel method to reveal drug targets
6. Tumor-killing virus selectively targets diseased brain cells
7. Enzyme structure reveals new drug targets for cancer and other diseases
8. GPS for the Prostate: System Keeps Radiation Therapy on Target
9. NeoStrata Clinical Findings Reveal Benefits of Combining Glycolic Acid Peels and Targeted Home Care With Microdermabrasion for Optimized Treatment of Photodamaged Skin
10. Childrens Hospital scientists identify possible target for prevention and treatment of pneumonia
11. Campaign Targets Noise-Induced Hearing Loss in Kids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... Mt. Angel Vitamins, a 5-year-old ... rebranding effort. This includes the introduction of new packaging and messaging, as well ... we learned that a simple, proactive approach to wellness is important to vitamin ...
(Date:3/27/2017)... RICHEY, Fla. (PRWEB) , ... March 27, 2017 ... ... drug overdose deaths soared 167%,(1) with opioids alone responsible for over 33,000 of ... Kevin McCarty has sponsored Assembly Bill (AB) 1512, which proposes a tax on ...
(Date:3/26/2017)... Ohio (PRWEB) , ... March 26, 2017 , ... ... doctors worldwide to receive the RealSelf 100 Award, a prestigious award honoring the ... cosmetic procedures and to find and connect with doctors and clinics. , In ...
(Date:3/24/2017)... ... 2017 , ... Clean Earth, Inc., a leader in providing ... materials announced today the acquisition of privately owned AERC Recycling Solutions ... facilities and a vast array of additional technologies, services, and new markets to ...
(Date:3/24/2017)... ... 24, 2017 , ... Infectious disease affects billions of people ... States, it’s a threat that is constantly changing and evolving. Mediaplanet's “Fighting Infection” ... strategies for the healthcare community to help decrease the number of completely preventable ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets ... Business Report" report to their offering. ... This report analyzes the worldwide markets for Dental Implants ... Canada , Japan , ... , and Rest of World. Annual estimates and ...
(Date:3/24/2017)... 2017 Research and Markets has announced the addition ... report to their offering. ... The IPF pipeline is very strong with a total of 97 drug ... Biogen and Sanofi are involved in the development of the IPF therapeutics. ... in Phase III stage, 15 are in Phase II stage, 12 are ...
(Date:3/24/2017)... , Mar 24, 2017 Research and Markets ... Global Strategic Business Report" report to their offering. ... The report provides separate comprehensive analytics for ... Europe , Asia-Pacific , ... are provided for the period 2015 through 2022. Also, a six-year historic ...
Breaking Medicine Technology: